Acadia Pharma (ACAD) Misses Q4 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/25/2026
- Wall Street closes lower to end rocky week
- Meta's capital-raising plans expose a major weakness in the AI boom
- Oil prices jump $3 on Houthi attacks, oil spill, highest settlement since April
- BofA flags further downside risk for stocks, yields and dollar
- SpaceX cell-site ambitions lift tower stocks and weigh on carriers
Tweet
Share
E-mailGet Alerts ACAD Hot Sheet
Price: $19.73 -2.86%
Revenue Growth %: +19.3%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Revenue Growth %: +19.3%
Financial Fact:
Collaborative revenues: 5.27M
Today's EPS Names:
FCNCA, FCNCA, RCBC, More
Join SI Premium – FREE
Acadia Pharma (NASDAQ: ACAD) reported Q4 EPS of ($0.28), $0.02 worse than the analyst estimate of ($0.26).
For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sachs Downgrades Norsk Hydro SA (NHY:NO) (NHYDY) to Neutral
- AMTD Digital reports $1.2B in total assets, $42.4M profit
- BioNTech and Bristol Myers Squibb report Phase 2 data for pumitamig in NSCLC
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
